NCT07443176

FCI-Glioblastoma Study

Applying New MRI Technology to Improve Outcomes From Chemoradiotherapy Treatment for Adult Patients With Glioblastoma

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 18 (estimated)
• Sponsor: University of Aberdeen · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can tell the difference between tumour growth (progression) and 'pseudo-progression' (which looks like tumour but is not cancerous tissue) in patients with glioblastoma. The main question it aims to answer is: • Can FCI differentiate glioblastoma progression from pseudo-progression? Participants will undergo a standard MRI scan and an FCI scan, three times during the study. One before starting adjuvant chemotherapy, another one after three cycles and one at the end of treatment.

Conditions

• Glioblastom WHO Grade 4

Interventions

Type	Name	Description
OTHER	Baseline Field-Cycling Imaging research scan	FCI scan at baseline
OTHER	Baseline 3T MRI research scan	MRI scan at baseline
OTHER	Second Field-Cycling Imaging research scan	FCI scan after three cycles of chemotherapy
OTHER	Second 3T MRI research scan	MRI scan after three cycles of chemotherapy
OTHER	Final Field-Cycling Imaging research scan	FCI scan at the end of chemotherapy
OTHER	Final 3T MRI research scan	MRI scan at the end of chemotherapy

Timeline

• Start date: 2026-02-01
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2026-03-02
• Last updated: 2026-03-02

Locations

1 site across 1 country: United Kingdom